Related Experiment Video
Updated: Jul 14, 2026
05:52
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Sentinel lymph node biopsy in colon cancer: a prospective multicenter trial
Andreas E Bembenek1, Robert Rosenberg, Elke Wagler
1Department of Surgery and Surgical Oncology, Robert-Rössle-Klinik, Charité University Medicine Berlin, Campus Buch at HELIOS-Klinikum Berlin, Lindenberger Weg 80, 13125 Berlin, Germany.
Annals of Surgery
|May 25, 2007
Summary
Sentinel lymph node biopsy (SLNB) in colon cancer has a high false-negative rate, particularly in patients with higher BMI. Further research is needed to clarify the clinical impact of micrometastases detected by SLNB.
Area of Science:
- Oncology
- Surgical Pathology
- Cancer Staging
Background:
- The clinical significance of sentinel lymph node biopsy (SLNB) for colon cancer remains debated.
- Accurate nodal status prediction is crucial for treatment decisions in colon cancer.
Purpose of the Study:
- To prospectively evaluate the clinical utility of SLNB in predicting nodal status in colon cancer patients.
- To identify factors influencing SLNB detection and accuracy.
Main Methods:
- A prospective multicenter trial involving colon cancer patients.
- Intraoperative SLN identification using subserosal blue dye injection.
- Step sectioning and immunohistochemistry (IHC) for SLN analysis.
Main Results:
- SLN detection rate was 85% (median 2 SLNs).
- Factors like center experience and BMI affected detection rates.
- The false-negative rate for SLNB was 46%, significantly influenced by BMI.
- SLNB identified micrometastases (MM/ITC) in 21% of patients initially staged as pN0.
Conclusions:
- SLNB's role in conventional colon cancer staging is currently unclear.
- Technical refinements are necessary for definitive conclusions.
- SLNB detects MM/ITC in a significant proportion of stage II patients, warranting further investigation into prognostic and therapeutic implications.
